Analysis of patients with lung cancer with compramised performance status
Not Applicable
- Conditions
- Health Condition 1: null- Lung Cancer Patients
- Registration Number
- CTRI/2017/12/010918
- Lead Sponsor
- ot Applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
We will include all patients whose details have been entered in the prospectively maintained medical oncology database of SCLC patients with PS >2 who were offered chemotherapy from 2010 onwards (to date).
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the percentage of patients who had an improvement in disease-attributable symptoms.Timepoint: At first followup after chemotherapy, i.e 7-days after chemotherapy and before cycle 2 of chemotherapy, i.e. at 3 weeks after cycle 1 of chemotherapy, and at the conclusion of chemotherapy (18 weeks after cycle 1 of chemotherapy)
- Secondary Outcome Measures
Name Time Method 1. To determine the percentage of patients who were able to receive subsequent standard course of chemotherapy. <br/ ><br>2. Overall survival <br/ ><br>3. Progression-free survival <br/ ><br>4. Response rate to first line chemotherapy <br/ ><br>5. To evaluate the factors that affected toxicity. <br/ ><br>6. To evaluate the factors that affected survival. <br/ ><br>Timepoint: 1. 21 weeks after date of start of chemotherapy <br/ ><br>2 Death <br/ ><br>3. AT disease progression <br/ ><br>4,5 & 6- After 9 weeks & after 21 weeks